Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase II Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC

NCT03823807 is registered in ClinicalTrials.gov with Nanjing Sanhome Pharmaceutical, Co., Ltd. as lead sponsor.

NCT NCT03823807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03823807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase II Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC
Lead sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2019
Completion date
March 31, 2021
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer